Targeting STAT3 inhibition to reverse cisplatin resistance
Cisplatin is one of the most frequently used chemotherapeutic agents for treatment of a wide range of cancer types. Nevertheless, the intrinsic or acquired resistance to cisplatin remains a major obstacle for cancer therapy. There are a number of factors contributing to the onset of this phenotype r...
Main Authors: | Chao-Yue Sun, Juan Nie, Jie-Peng Huang, Guang-Juan Zheng, Bing Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332219314556 |
Similar Items
-
Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
by: W.J. Sheng, et al.
Published: (2013-08-01) -
Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3)
by: Kandala Prabodh K, et al.
Published: (2012-01-01) -
STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma
by: Ana Paula Morelli, et al.
Published: (2021-10-01) -
TARGETING COCHLEAR INFLAMMATION FOR THE TREATMENT OF CISPLATIN OTOTOXICITY
by: Kaur, Tejbeer
Published: (2012) -
Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
by: Mingjing Shen, et al.
Published: (2019-04-01)